Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant MET (Telisotuzumab Biosimilar) antibody

The Humanized Monoclonal anti-MET (Telisotuzumab Biosimilar) antibody (ABIN7851094) specifically detects MET (Telisotuzumab Biosimilar) in ELISA and FACS. The antibody is reactive with Human samples.
Catalog No. ABIN7851094
$292.43
Plus shipping costs $50.00
Shipping to: United States
Delivery in 12 to 15 Business Days

Quick Overview for Recombinant MET (Telisotuzumab Biosimilar) antibody (ABIN7851094)

Target

MET (Telisotuzumab Biosimilar)

Antibody Type

Recombinant Antibody

Reactivity

Human

Host

  • 2
  • 1
Humanized

Clonality

  • 2
  • 1
Monoclonal

Conjugate

  • 3
This MET (Telisotuzumab Biosimilar) antibody is un-conjugated

Application

ELISA, Flow Cytometry (FACS)

Grade

Research Grade
  • Purpose

    Anti-MET(telisotuzumab biosimilar) mAb

    Isotype

    IgG1, K214R, K222del, T223C, T225del, kappa
  • Application Notes

    ELISA 1:5000-10000, Flow Cyt 1:100

    Comment

    Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals.

    Restrictions

    For Research Use only
  • Format

    Lyophilized

    Reconstitution

    Please see Certificate of Analysis for specific instructions of reconstitution.

    Buffer

    Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8 % trehalose is added as protectants before lyophilization.

    Storage

    -20 °C,-80 °C

    Storage Comment

    Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized antibodies are shipped at ambient temperature.

    Expiry Date

    12 months
  • Target

    MET (Telisotuzumab Biosimilar)

    Alternative Name

    telisotuzumab Biosimilar

    Target Type

    Biosimilar

    Background

    Synonyms Target:MET
    Synonyms Antibody:ABT-700,hz224G11

    UniProt

    P08581
You are here:
Chat with us!